A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

November 24, 2025

Study Completion Date

April 3, 2026

Conditions
Uncontrolled HypertensionResistant Hypertension
Interventions
DRUG

Baxdrostat

"Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm"

DRUG

Placebo

Placebo tablet administered orally, once daily (QD).

Trial Locations (93)

1112

Research Site, Quezon City

2250

Research Site, Gosford

3029

Research Site, Hoppers Crossing

4305

Research Site, Ipswich

5000

Research Site, Iloilo City

Research Site, Ankara

8000

Research Site, Bahía Blanca

22030

Research Site, Edirne

33343

Research Site, Mersin

35575

Research Site, Karşıyaka

38039

Research Site, Kayseri

41380

Research Site, Kocaeli

46100

Research Site, Kahramanmaraş

70000

Research Site, Hochiminh

100000

Research Site, Hanoi

100029

Research Site, Beijing

100044

Research Site, Beijing

110004

Research Site, Shenyang

110016

Research Site, Shenyang

111539

Research Site, Moscow

119991

Research Site, Moscow

121552

Research Site, Moscow

124009

Research Site, Panjin

129327

Research Site, Moscow

135022

Research Site, Meihekou

150001

Research Site, Ha’erbin

153012

Research Site, Ivanovo

195067

Research Site, Saint Petersburg

197341

Research Site, Saint Petersburg

200025

Research Site, Shanghai

200040

Research Site, Shanghai

210009

Research Site, Nanjing

221000

Research Site, Xuzhou

225001

Research Site, Yangzhou

230601

Research Site, Hefei

233004

Research Site, Bengbu

272100

Research Site, Changzhou

274099

Research Site, Heze

300457

Research Site, Tianjin

310014

Research Site, Hangzhou

330009

Research Site, Nanchang

332000

Research Site, Jiujiang

400010

Research Site, Chongqing

400014

Research Site, Chongqing

400042

Research Site, Chongqing

410015

Research Site, Changsha

415003

Research Site, Changde

430010

Research Site, Wuhan

430022

Research Site, Wuhan

430033

Research Site, Changsha

430060

Research Site, Wuhan

471000

Research Site, Luoyang

510100

Research Site, Guangzhou

572000

Research Site, Sanya

590016

Research Site, Belagavi

610041

Research Site, Chengdu

618000

Research Site, Deyang

637900

Research Site, Nanchong

643021

Research Site, Zigong

700000

Research Site, Ho Chi Minh City

Research Site, Hochiminh City

712000

Research Site, Xianyang

750001

Research Site, Yinchuan

750004

Research Site, Xianyang

900000

Research Site, Can Tho

C1426

Research Site, CABA

C1419AHL

Research Site, Ciudad de Buenos Aires

T4000ICL

Research Site, San Miguel de Tucumán

B2900DPA

Research Site, San Nicolás de los Arroyos

02450

Research Site, Coffs Harbour

014010

Research Site, Baotou

030024

Research Site, Taiyuan

Unknown

Research Site, Tianjin

Research Site, Hong Kong

00000

Research Site, Hong Kong

560 092

Research Site, Bangalore

103-0027

Research Site, Chūōku

260-0804

Research Site, Chūōku

430-0929

Research Site, Hamamatsu

890-8520

Research Site, Kagoshima

306-0232

Research Site, Koga-shi

153-0051

Research Site, Meguro-ku

108-0073

Research Site, Minatoku

505-8510

Research Site, Minokamo Shi

530-8480

Research Site, Osaka

171-0014

Research Site, Toshima-ku

305-0861

Research Site, Tsukuba

236-0004

Research Site, Yokohama

03080

Research Site, Seoul

03722

Research Site, Seoul

04763

Research Site, Seoul

05505

Research Site, Seoul

06800

Research Site, Ankara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY